{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-239008","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.065136+00:00","generated_at":"2026-05-17T03:51:24.928930+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"EyePoint initiates Phase 3 DURAVYU DME program; first patient Q1 2026; dual MOA data","bullets":["First patient dosing in pivotal Phase 3 DME trials (COMO and CAPRI) expected Q1 2026; trials enroll ~240 patients each.","Non-inferiority design vs aflibercept; primary endpoint is BCVA change from baseline at weeks 52 and 56.","New preclinical data shows vorolanib inhibits IL-6 mediated inflammation via JAK receptors, adding to VEGF blockade.","Company had positive end-of-Phase 2 meeting with FDA; DURAVYU also in Phase 3 for wet AMD.","Estimated cash and investments as of Sept 30, 2025 included in investor presentation (not specified)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-239008","json":"https://secwatch.observer/filing/0001193125-25-239008.json","markdown":"https://secwatch.observer/filing/0001193125-25-239008.md","text":"https://secwatch.observer/filing/0001193125-25-239008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312525239008/0001193125-25-239008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312525239008/d14832d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:51:24.928930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}